191 related articles for article (PubMed ID: 12230856)
1. Life, death, and monopoly rights in a democratic society.
Smith SJ
Am J Bioeth; 2002; 2(3):43-4. PubMed ID: 12230856
[No Abstract] [Full Text] [Related]
2. Patents: the public interest versus the private privilege.
Parsi KP; Egan EA
Am J Bioeth; 2002; 2(3):45-6. PubMed ID: 12230857
[No Abstract] [Full Text] [Related]
3. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
Resnik DB; DeVille KA
Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
[No Abstract] [Full Text] [Related]
4. Not taking, just borrowing: government use of patented drugs.
Ossorio PN
Am J Bioeth; 2002; 2(3):51-2. PubMed ID: 12230861
[No Abstract] [Full Text] [Related]
5. The Cipro patent and bioterrorism.
Kaye KS; Kaye D
Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
[No Abstract] [Full Text] [Related]
6. Compulsory licensure: the case of Cipro and beyond.
Chakrabarty AM
Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
[No Abstract] [Full Text] [Related]
7. It is not unethical, though it is often unwise, to override patents.
Leventer H
Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860
[No Abstract] [Full Text] [Related]
8. Who are the guardians guarding?
Trachtman H
Am J Bioeth; 2002; 2(3):46-8. PubMed ID: 12230858
[No Abstract] [Full Text] [Related]
9. Beyond government intervention: drug companies and bioethics.
Dresser R
Am J Bioeth; 2002; 2(3):42-3. PubMed ID: 12230855
[No Abstract] [Full Text] [Related]
10. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
11. Patent immorality?
Bloche MG; Jungman ER
Am J Bioeth; 2002; 2(3):48-9. PubMed ID: 12230859
[No Abstract] [Full Text] [Related]
12. A license to print money?
Nat Biotechnol; 2006 Jun; 24(6):593. PubMed ID: 16763570
[No Abstract] [Full Text] [Related]
13. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
14. The burgeoning science of genetics and the impact on public policy.
Hatch OG
J Biolaw Bus; 2004; 7(4):3-6. PubMed ID: 15675088
[TBL] [Abstract][Full Text] [Related]
15. India's IP snub.
Jayaraman KS
Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392000
[No Abstract] [Full Text] [Related]
16. Gene patents--a pharmaceutical perspective.
Tribble JL
Camb Q Healthc Ethics; 1998; 7(4):429-32. PubMed ID: 9752585
[No Abstract] [Full Text] [Related]
17. Four rebuffs for Cabilly.
Waltz E
Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392001
[No Abstract] [Full Text] [Related]
18. Patent crunch pending.
Wadman M
Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
[No Abstract] [Full Text] [Related]
19. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
20. Promega changes tack in battle over patent.
Knight J
Nature; 2003 Nov; 426(6965):373. PubMed ID: 14647346
[No Abstract] [Full Text] [Related]
[Next] [New Search]
